G+FLAS said it provides CRISPR-related research services, tools, and reagents and applies CRISPR technology to develop drugs and produce genome-edited plants.
The platform, based on the firm's Hi-C technology, is designed to assembly viral genomes from metagenomic samples and associate them with their microbial hosts.
The Paris-based company plans to use the nucleic acid modification technology to synthesize qPCR probes for use in diagnostics, among other biomolecules.
The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.
The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.
PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
Initial partners in the program include Thermo Fisher Scientific, GNS Healthcare, DNAnexus, Personal Genome Diagnostics, and the Wellcome Sanger Institute.
A federal court ruled this week that IonPath's MIBIscope does not infringe on Fluidigm's technology, though the company has indicated it will likely appeal.
The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.
The firm said it intends to apply to obtain FDA Emergency Use Authorization and 510(k) clearance for a panel that detects respiratory targets in a single test.
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
The single-cell and spatial genomics company is planning a 50 percent increase in headcount, including the addition of 100 people to its commercial organization.
The deal centers around Metabolon's platform for identifying pharmacodynamic, efficacy, and response biomarkers and tracking changes in biological pathways.
The proteomics firm is expected to receive $514 million in proceeds through the deal, including a $425 million private investment in public equity (PIPE) transaction.
